PARIS (Reuters) -French drugmaker Sanofi said on Monday it had entered exclusive talks to sell a 50% controlling stake in its ...

The offer is made at a price of Rs 4,982.05 per share, aggregating to a total consideration of up to Rs 2,983.23 crore, ...

Earlier this month Sanofi revealed talks were ongoing with CD&R, and has now confirmed the negotiations could result in the ...

Globally, buyout deals were on track to finish the year at $521bln, up 18% from 2023, with the rise driven by a higher average deal size rather than more deals ...

Sanofi and CD&R announce a plan to join forces to fuel Opella’s ambitions as a French-headquartered, global consumer healthcare champion. Sanofi and CD&R have entered exclusive negotiations for the ...

Sanofi said its Opella business has been valued at around 16 billion euros (USD17.38 billion), or 14 times EBITDA in 2024 ...

French drama over sovereign paracetamol is really about a deeper ailment: underinvestment.

The French drugmaker on Monday announced progress on a deal to sell 50% of its over-the-counter division to Clayton Dubilier ...

Under the proposed deal, the PE firm would take a controlling 50% stake in Sanofi’s Opella unit, with state-owned Bpifrance ...

Sanofi will sell a 50% controlling stake in consumer healthcare unit Opella to private equity firm CD&R, with the French ...

French drugmaker Sanofi’s confirmation yesterday that it plans to sell a controlling stake in its over-the-counter unit to a ...

Sanofi is now in “exclusive negotiations” with U.S. private equity firm Clayton, Dubilier & Rice (CD&R) to sell a 50% ...